![]() |
市场调查报告书
商品编码
1423673
到 2030 年儿童用灌注系统市场预测:按产品、应用、最终用户和地区分類的全球分析Pediatric Perfusion Systems Market Forecasts to 2030 - Global Analysis By Product, By Application (Cardiac Surgeries, Organ Transplantation, Extracorporeal Life Support and Other Applications), End User and By Geography |
2023年,全球儿童用灌注系统市场价值为3.4696亿美元,预计到2030年将达到6.2616亿美元,预测期内复合年增长率为8.8%。
儿童用灌注系统是专门为在心血管手术期间需要心肺体外迴圈的婴幼儿和儿童创建的医疗装置。这些系统是根据儿童独特的生理机能量身量身定制,包括小型氧气输送机、帮浦、管道和监测设备。这些系统安全有效地支持儿童心血管手术,同时在手术过程中维持补氧、温度调节和血液循环等关键功能,同时考虑年轻患者的独特需求。
根据美国心臟协会 2022 年情况说明书,先天性心臟疾病预计每年将影响美国约 4 万名婴儿。
先天性心臟疾病发生率增加
全球婴幼儿和儿童先天性心臟疾病盛行率不断上升,是儿童用灌注系统市场的主要驱动力。由于认识的提高和诊断能力的提高,更多的病例可以更早被发现并需要先进的心血管手术。儿童用灌注系统在这些手术中发挥关键作用,为儿童患者的小解剖结构和独特的生理需求提供专门的支持。由于先天性心臟疾病的增加,心血管手术的需求不断增加,对有效灌注系统的需求也随之增加。
设备和流程高成本
儿童用灌注系统和相关程序的高成本是市场的主要抑制因素。为儿童患者量身定制的设备的特殊性,加上严格的安全标准和先进技术,导致成本上升。此外,维护和升级这些系统的成本以及对高技能人员的需求进一步增加了整体成本。儘管儿童心血管手术迫切需要这些系统,但高成本限制了某些医疗机构和地区的使用,阻碍了这些系统的广泛普及。
对客製化解决方案的需求不断增长
儿童患者有不同的解剖和生理需求,并且越来越重视客製化系统和技术来适应这些变化。专注于适应性强、针对患者的解决方案(例如可调泵、紧凑型供氧设备和专用监测设备)的公司可以利用这一趋势。提供满足特定患者需求的客製化选项不仅可以改善患者的治疗效果,还可以建立竞争优势并促进儿童用灌注系统的创新和市场扩张。
快速的技术变革
快速的技术创新对市场构成威胁,因为它有可能导致现有系统过时。持续的进步可以缩短设备的生命週期并加速当前系统的淘汰。这需要频繁升级和投资新技术,从而增加医疗机构的成本。此外,需要对员工进行更新系统培训并确保与不断发展的标准相容,这可能会带来物流的挑战。技术的快速发展可能会限制对当前解决方案的投资并影响市场稳定性。
COVID-19 的爆发干扰并影响了择期手术市场,包括儿童心血管手术手术,这些系统在其中发挥关键作用。由于医院容量减少、资源重新分配和安全措施,非紧急手术被推迟。因此,对儿童用灌注系统的需求暂时下降,影响了市场成长。然而,儘管面临这些挑战,许多儿童心血管手术的紧迫性仍然保持着一定的需求。
预计儿童用氧气供应领域在预测期内将是最大的
由于儿童用氧气输送装置在儿童心血管手术期间提供必要的氧气输送支援方面发挥关键作用,因此预计将占据大部分市场。专门的氧气输送设备对于这些手术至关重要,因为它们需要低血容量和针对儿童独特生理机能的精确氧气输送。此外,先天性心臟疾病发病率的上升和儿童心血管手术的需求正在推动对高效、适应性强的氧气输送设备的需求,使这一领域成为儿童用灌注系统的基石,并增加了小儿心臟手术的需求。我们优势背后的驱动力。
预计製药和生物技术公司在预测期内将表现出最高的复合年增长率。
由于专注于儿童用灌注系统的研究和开发的增加,製药和生物技术领域预计将出现最高的成长率。这些公司广泛投资于创新技术、药物开发和儿童心血管手术专用设备。随着对儿童患者客製化解决方案的日益重视,製药和生物技术公司在开发先进灌注系统方面处于领先地位,推动了该领域在预测期内的预期高成长率。
由于先进的医疗基础设施、大量的研发投资以及先天性心臟疾病的高盛行率,预计北美将占据最大的市场占有率。此外,该地区还设有儿童心臟中心,研究机构与製药公司之间的协作系统也已建立。有利的报销政策和主要市场参与者的存在进一步增强了北美在采用和实施先进儿童用灌注系统方面的优势,确保了重要的市场占有率。
由于医疗保健支出增加、儿童心臟护理意识增强以及儿童人口不断增长,预计亚太地区将出现显着增长。新兴国家的医疗保健基础设施和技术采用不断改善,推动了对先进灌注系统的需求。此外,与全球公司的合作、政府倡议以及儿童心血管手术中心的扩张正在为该地区在先进儿童用灌注系统的实施和整合方面发挥巨大的成长潜力做出贡献。
According to Stratistics MRC, the Global Pediatric Perfusion Systems Market is accounted for $346.96 million in 2023 and is expected to reach $626.16 million by 2030 growing at a CAGR of 8.8% during the forecast period. Pediatric perfusion systems are specialised medical setups crafted specifically for infants and children requiring cardiopulmonary bypass during cardiac surgeries. Tailored to their unique physiologies, these systems include smaller oxygenators, pumps, tubing and monitoring devices. They maintain vital functions like oxygenation, temperature control and blood circulation during procedures, ensuring safe and effective support for pediatric cardiac surgery while considering the unique needs of younger patients.
According to American Heart Association, Inc.'s fact sheet 2022, congenital heart defects are expected to affect around 40,000 infants in the U.S. each year.
Rising incidence of congenital heart defects
The increasing prevalence of congenital heart defects among infants and children globally serves as a significant driver in the pediatric Perfusion systems market. With rising awareness and improved diagnostic capabilities, more cases are being identified early, necessitating advanced cardiac surgeries. Pediatric perfusion systems play a crucial role in these surgeries, providing specialised support tailored to the smaller anatomies and unique physiological requirements of pediatric patients. As the demand for corrective cardiac procedures rises due to the growing incidence of congenital heart defects, the need for effective perfusion systems amplifies accordingly.
High cost of equipment and procedures
The high cost associated with pediatric perfusion systems and related procedures poses a significant restraint on the market. The specialised nature of equipment tailored for pediatric patients, coupled with stringent safety standards and advanced technologies, contributes to elevated costs. Additionally, the expenses incurred in maintaining and upgrading these systems, along with the need for highly skilled personnel, further escalate the overall expenditure. This high cost limits accessibility for certain healthcare facilities or regions, hindering widespread adoption despite the critical need for these systems in pediatric cardiac surgeries.
Growing demand for customized solutions
Pediatric patients exhibit diverse anatomies and physiological needs, and there's a growing emphasis on tailored systems and technologies to address these variations. Companies focusing on adaptable, patient-specific solutions, such as adjustable pumps, smaller oxygenators, and specialised monitoring devices, can capitalise on this trend. Offering customised options that cater to specific patient requirements not only enhances patient outcomes but also establishes a competitive edge, fostering innovation and market expansion in pediatric perfusion systems.
Rapid technological changes
Rapid technological changes pose a threat to the market due to the risk of rendering existing systems obsolete. Continuous advancements may lead to shorter lifecycles for equipment, potentially making current systems outdated faster. This necessitates frequent upgrades or investments in newer technologies, increasing costs for healthcare facilities. Additionally, the need for training staff on updated systems and ensuring compatibility with evolving standards can create logistical challenges. This swift pace of technological evolution might deter investments in current solutions, impacting market stability.
The COVID-19 pandemic has influenced the market by causing disruptions in elective surgeries, including pediatric cardiac procedures, where these systems are crucial. Reduced hospital capacities, redirected resources, and safety measures resulted in deferred non-emergency surgeries. This decreased demand for pediatric perfusion systems temporarily, affecting market growth. However, the urgent nature of many pediatric cardiac surgeries has sustained some demand despite these challenges.
The pediatric oxygenators segment is expected to be the largest during the forecast period
The pediatric oxygenators segment is anticipated to dominate due to its pivotal role in providing essential oxygenation support during pediatric cardiac surgeries. As these procedures require precise and tailored oxygenation for smaller blood volumes and unique pediatric physiology, specialised oxygenators are crucial. Additionally, the rising incidence of congenital heart defects and the demand for pediatric cardiac interventions drive the need for efficient and adaptable oxygenators, positioning this segment as a cornerstone in pediatric perfusion systems and thus driving its expected market dominance.
The pharmaceutical and biotech companies segment is expected to have the highest CAGR during the forecast period
The pharmaceutical and biotech companies segment anticipates the highest growth rate owing to increased research and development focused on pediatric perfusion systems. These companies invest extensively in innovative technologies, drug development and specialised equipment catering to pediatric cardiac surgeries. With a growing emphasis on tailored solutions for pediatric patients, pharmaceutical and biotech firms are leading in developing advanced perfusion systems, thus driving the projected high growth rate in this segment during the forecast period.
North America is positioned to hold the largest market share due to advanced healthcare infrastructure, substantial R&D investments, and a high prevalence of congenital heart defects. Additionally, the region boasts well-established pediatric cardiac centers and collaborations between research institutes and pharmaceutical companies. Favorable reimbursement policies and the presence of key market players further contribute to North America's dominance in adopting and implementing sophisticated pediatric perfusion systems, securing a significant market share.
The Asia-Pacific region is set to experience significant growth owing to the rising healthcare expenditure, increasing awareness about pediatric cardiac care and a growing pediatric population. Emerging economies are witnessing improvements in healthcare infrastructure and technology adoption, fostering the demand for advanced perfusion systems. Moreover, collaborations with global players, government initiatives and expanding pediatric cardiac surgery centres contribute to the region's substantial growth potential in adopting and integrating sophisticated pediatric perfusion systems.
Key players in the market
Some of the key players in Pediatric Perfusion Systems Market include Baxter International Inc., Braile Biomedica, Edwards Lifesciences Corporation, Getinge Group, Hemovent GmbH, LeMaitre Vascular, Inc., LivaNova, Medtronic, MicroPort Scientific Corporation, Nipro Medical Corporation, Perfusion.com, Inc., Sorin Group, Spectrum Medical, Stryker Corporation, Terumo Cardiovascular and Xenios AG.
In December 2023, Vascular Perfusion Solutions (VPS), Inc., is a San Antonio based medical device startup company focused on developing novel prolonged organ preservation technologies prior to transplantation, has received a $25,000 grant from the Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC).
In March 2023, LivaNova PLC, a market-leading medical technology and innovation company, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for the Essenz HLM from Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).